Ads
related to: mannkind news clinical trialscancer.osu.edu has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
MannKind (NAS: MNKD) announced breathtaking news this week -- literally. The biotech completed patient recruitment for two phase 3 clinical trials for its insulin inhalant Afrezza. The ...
Today, MannKind announced that its two Phase 3 Afrezza clinical trials have completed patient enrollment, and this will help the company stay on track to file for FDA approval in Q3 of 2013.
MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes VALENCIA, Calif.--(BUSINESS WIRE)-- MannKind Corporation (Nasdaq: MNKD) today announced that all follow-up ...
MannKind Completes Patient Recruitment in Two Phase 3 Clinical Studies of AFREZZA VALENCIA, Calif.--(BUSINESS WIRE)-- MannKind Corporation (Nasdaq: MNKD) today announced that it has completed ...
CORRECTING and REPLACING MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes VALENCIA, Calif.--(BUSINESS WIRE)-- Second graph under Other ...
The small steps are largely behind biotech company MannKind (NAS: MNKD) . Over the course of the past few years, the company navigated 61 different clinical studies for its Afrezza insulin ...
You could say that MannKind is treading water a bit these days -- at least from the outside perspective. The company won't announce results from its phase 3 studies of inhalable insulin Afrezza ...
Biopharmaceutical company MannKind (NAS: MNKD) is seeking FDA approval for its inhalable insulin drug, Afrezza. A decision in 2013 is expected, and the company hopes to get this drug to market as ...